Clinical Trials · NCT05983198
Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT
- Phase
- Phase 1
- Recruitment status
- Active Not Recruiting
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 33
- Start date
- Nov 2023
- Locations
- 10 sites, 4 countries
- Primary endpoint
- Phase I Dose Escalation: Incidence and severity of DLTs during the DLT observation period